# A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

> **NCT07285967** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou Yirui Pharmaceutical Technology Co., Ltd** · enrollment: 64 (estimated)

## Conditions studied

- Safety
- Tolerability
- Pharmacokinetics

## Interventions

- **DRUG:** Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07285967
- **Lead sponsor:** Hangzhou Yirui Pharmaceutical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285967, "A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07285967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*